TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04320147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artemia
Description: Before prostate biopsy, all patients be preceded by mpMRI.MR-targeted biopsy using Artemis device fusion of MRI and ultrasound images would be performed. MR targeted biopsy would be performed by radiologist.
Study: NCT01848340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744B (sodium salt) containing 14C-GSK1265744B
Description: A white to slightly colored nonsterile crystalline powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg GSK1265744B
Description: This is GSK1265744B (sodium salt of GSK1265744), lactose monohydrate, Microcrystalline cellulose, hypromellose, sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, Opadry film-coating, white OY-S-28876 tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose, Opadry film-coating, white OY-S-28876 tablet
Study: NCT02865122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTRA-9620
Description: Oral daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTRA-9620
Description: Oral daily dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral daily dose
Study: NCT02472366

Intervention type: DRUG
Group type: OTHER
Intervention: ILUVIEN

Intervention type: DRUG
Group type: OTHER
Intervention: ILUVIEN
Study: NCT01745783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells autologous
Description: Infusion of mesenchymal cells from autologous bone marrow in a dose of 1-2x106 cells / kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Lactated Ringer's solution, 2.5% glucose and 1% human albumin.
Study: NCT02753335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GMI and Desensitization
Description: Graded Motor Imagery (GMI) is used to treat chronic pain conditions and movement problems related to alterations in the nervous system such as CRPS, postamputation limb pain and back pain. The patient is trained in monitored steps. The three treatment components include left/right discrimination training, motor imagery exercises and mirror observations of the unaffected limb, appearing as the affected limb. They are performed sequentially, but require a flexible approach to suit the individual patient. The imagined movements have been demonstrated to activate motor cortical areas similar to those activated in the actual execution of that movement.~Desensitization (D) is used to decrease hyperalgesia by repeated tactile stimulation of the affected area with various materials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Desensitization
Description: Desensitization (D) is used to decrease hyperalgesia and allodynia by repeated tactile stimulation of the affected area with various materials.
Study: NCT00911781

Intervention type: OTHER
Intervention: No intervention
Description: We are only asking for photographs from parents.
Study: NCT01510262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Socio-Contextual Intervention
Description: 1. Develop strengths based case management intervention using input from interviews with repeat STI patients, consultants, \& piloting.~2. Recruit/enroll in the intervention 500 subjects (50% women; African American focus).~3. After subjects receive STI diagnosis, treatment,\& partner notification services, randomly assign subjects to:~   A. The STI strengths-based prevention case management, or B. Standard care.~4. Assess participants' risk behavior, determinants of behavior \& quality of life. Investigators will assess the incidence of new STI \& test the efficacy of the intervention relative to control.~5. Conduct a qualitative evaluation. Investigators will sample repeaters and non-repeaters from the experimental group.~6. Conduct cost effectiveness analyses of intervention compared to the standard.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Currently, the total time spent in an STI exam w/men is 30 minutes \& 60 w/women. More time is devoted to patients with sexual assault hx. Reason for the visit, symptoms, STI hx, contraception, condom use, number/gender of partners \& number/type of sexual activities are assessed. The nurse takes a health hx and asks about typical HIV risks behavior. Due to time the risk assessment is 5 minutes. A risk reduction kit including condoms is issued. Information includes symptoms/treatment of STI, location of sexual health clinics, location of free condoms \& testing/treatment resources. Referral information is provided when needed \& more involved w/sexual assault survivors. Partner notification is conducted w/syphilis and HIV. This didactic process follows the medical model.
Study: NCT00262925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Given IV
Study: NCT02325778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTI ablation Timing
Description: The timing of when the CTI ablation is performed. There are no other relevant interventions used in the procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTI ablation Timing
Description: The timing of when the CTI ablation is performed. There are no other relevant interventions used in the procedure.
Study: NCT01741662

Intervention type: OTHER
Group type: OTHER
Intervention: neuropsychological evaluation
Study: NCT05112133

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mulberry leaf extract
Description: Oral administration

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mulberry leaf extract
Description: Oral administration

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Oral administration
Study: NCT03547570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive heavy shoulder resistance training
Description: The training programme includes five exercises identified in literature to target scapular and rotator cuff muscles.
Study: NCT03838874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dose Bupivacaine
Description: 10 mg (2 mL of 0.5%) administered as an isobaric spinal anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: 70 mg (3.5 mL of 2%) administered as an isobaric spinal anesthetic
Study: NCT04170413

Intervention type: DRUG
Intervention: CeVUS
Description: Contrast enhanced voiding urosonography
Study: NCT00831844

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.
Study: NCT01938339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Multi-radiotracer PET/MR will be performed in patients with primary and recurrent prostate cancer
Study: NCT00831844

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.
Study: NCT00185198

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5g gel sachet, 5g+2.5g sachet or 2x5g sachets per day applied to the skin of the shoulders, arms or abdomen for 6 months followed by 12 months treatment with testosterone 1% gel as described for arm 1
Study: NCT00796523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Happiest Baby videotape
Description: a videotape demonstrating the Happiest Baby on the Block technique for calming crying infants

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: control videotape
Description: a videotape with general newborn care instructions
Study: NCT00761644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Day 1 of each 21 day cycle, beginning dose level 10 mg/m\^2 by vein over 3 hours.
Study: NCT00831844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00761644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Days 1, 8 \& 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes.
Study: NCT02527577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RopivacaIne chlorhydrate
Description: 3mg/kg injection Hour (H) 0, H12 ; H24, H36 ; H48
Study: NCT04022980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: HD-MTX containing induction chemotherapy (per standard of care) followed by Nivolumab consolidation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: HD-MTX containing induction chemotherapy (per standard of care) followed by Nivolumab consolidation.
Study: NCT00831844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01010178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macrolid, Theophylline, Inhaler Corticosteroids
Description: we have no permission to include them in detail because of privacy policy of mentioned journal for publication
Study: NCT03854500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: 0.4 mg/kg single bolus intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: 0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
Study: NCT01683526

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video laryngoscopy (Glidescope)
Study: NCT05324696

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: autoinflation device
Description: The authors developed a new standardized, inexpensive and simple device, based on Moniri. The Device is formed by a T tube with a unidirectional valve. A mask with the capacity of covering the child's mouth and nose, providing hermetic seal, and a balloon are connected to 2 ends of the T tube. Blowing the balloon trough the mask, with different types of maneuvers, will force the opening of the Eustachian tube and subsequent reabsorption of the middle ear effusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoinflation device
Description: The authors developed a new standardized, inexpensive and simple device, based on Moniri. The Device is formed by a T tube with a unidirectional valve. A mask with the capacity of covering the child's mouth and nose, providing hermetic seal, and a balloon are connected to 2 ends of the T tube. Blowing the balloon trough the mask, with different types of maneuvers, will force the opening of the Eustachian tube and subsequent reabsorption of the middle ear effusion.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: autoinflation device
Description: The authors developed a new standardized, inexpensive and simple device, based on Moniri. The Device is formed by a T tube with a unidirectional valve. A mask with the capacity of covering the child's mouth and nose, providing hermetic seal, and a balloon are connected to 2 ends of the T tube. Blowing the balloon trough the mask, with different types of maneuvers, will force the opening of the Eustachian tube and subsequent reabsorption of the middle ear effusion.
Study: NCT02198352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS - in single rising doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05286346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil 245mg
Description: 1 tablet q.d. for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300mg
Description: 1 tablet q.d. for 48 weeks
Study: NCT02179619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermalax(Deep)
Description: Dermalax(Deep) injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermalax(Deep)
Description: Dermalax(Deep) injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane
Description: Restylane Injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: Restylane Injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
Study: NCT01499589

Intervention type: PROCEDURE
Intervention: regional anesthesia
Description: regional anesthesia procedure

Intervention type: PROCEDURE
Intervention: regional anesthesia
Description: regional anesthesia procedure
Study: NCT02979327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall capsule
Description: 25 mg orally one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall capsule
Description: 25 mg orally one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Looks exactly like the study drug, but it contains no active ingredient. Taken one time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Looks exactly like the study drug, but it contains no active ingredient. Taken one time.
Study: NCT00622895

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow transplantation
Description: Undergo transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reduced intensity allogeneic hematopoietic stem cell transplantation
Description: Undergo transplantation
Study: NCT02527577

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: injection Hour (H) 0, H12 ; H24, H36 ; H48
Study: NCT03276455

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous CD34+ cells genetically modified
Description: Autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene. The target dose in the transduced product is 3x10\^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10\^6/Kg and a maximum dose of 20 x 10\^6/Kg, depending on the yield of cells. The product will be injected intraosseously following intravenous BU ±Flu ±Cy.
Study: NCT03089385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertension tool
Description: An algorithm developed by staff at UHN to help manage hypertension in hemodialysis patients.
Study: NCT04339244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RALRP under lower mean BP
Description: RALRP under regulation of lower mean BP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RALRP under lower mean BP
Description: RALRP under regulation of highly normal mean BP
Study: NCT00827138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2036
Description: 150 mg BID tablets, continuous dosing of 28 day cycles
Study: NCT03800940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fistulography and trans-drain occlusion
Description: 1. Fistulography: an 18G needle is inserted into the tube and diluted contrast medium is slowly injected into the tube.~2. Trans-drain occlusion: a 0.035-inch guidewire is inserted via the puncture needle. The drain tube is removed, cut at 4 cm proximal to the skin fixation site, and preserved for reinsertion. After inserting a 40cm 5Fr KMP catheter over the guidewire, the guidewire is removed. Afte rinsing the KMP catheter with 3ml 5% glucose water, withdraw the catheter and simultaneously inject glue (33%, 1:2, 0.5ml of NBCA + 1ml Lipiodol) into the catheter until the proximal 5cm of the catheter remains inside the tract. The guidewire is re-inserted through the catheter, and then the original drain tube is re-inserted over the guidewire. The guidewire is removed and the drain is fixed.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Fistulography
Description: Fistulography: an 18G needle is inserted into the tube and diluted contrast medium is slowly injected into the tube.
Study: NCT01037192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin
Description: vancomycin 30 mg/kg intravenous administered once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Description: vancomycin 15 mg/kg intravenous administered twice daily (standard dosing)
Study: NCT03338413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: 9 GMT modules will be administered in 9X2 hour sessions (ten groups). Manualized intervention; metacognitive strategies for improving attention and problem solving.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Description: 9 modules will be administered in 9x1 hour session (ten groups). Computerized Cognitive Training using commercially available web-based platforms based on neuroplasticity, developed to target skills such as attention, memory, speed of processing and executive functioning. Homework assignment between sessions.
Study: NCT00622895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Punch biopsy of skin involved with scleroderma
Study: NCT01745809

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Subjects will have a screening visit and, if they qualify to take part in the study, they will undergo a single bronchoscopy procedure. During the bronchoscopy, bronchoalveolar lavage (BAL) and bronchial brushings will be performed on each subject.

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Subjects will have a screening visit and, if they qualify to take part in the study, they will undergo a single bronchoscopy procedure. During the bronchoscopy, bronchoalveolar lavage (BAL) and bronchial brushings will be performed on each subject.
Study: NCT02058901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Study: NCT04500704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Almonertinib
Description: Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib plus carboplatin and pemetrexed
Description: Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.